In recent years, much of cancer research has been driven by new and novel therapies. These therapies include t-cell therapies and precision medicine. When undergoing t-cell therapy, a patient’s t-cells are extracted, engineered to target a biomarker (such as mesothelin, which is often attached to mesothelioma tumor cells but not healthy cells), and then reintroduced into the patient’s body. With precision medicine, a molecule or compound is used to target a mutation or pathway known to have a role in the development of mesothelioma.
The Novel Therapies for Mesothelioma session took place at the 2023 International Symposium on Malignant Mesothelioma in Washington, DC.
The presentation was led by:
Prasad Adusumilli, MD, Memorial Sloan Kettering Cancer Center
Raffit Hassan, MD, National Cancer Institute
This is a recording of a session at the 2023 International Symposium on Malignant Mesothelioma. This symposium is made possible by our generous sponsors: Belluck and Fox, LLP; Maune Raichle Hartley French & Mudd, LLC (MRHFM); Polaris Pharmaceuticals, Inc.; Bristol Myers Squibb; Merck; The Gori Law Firm; Ikena Oncology; Early Lucarelli Sweeney & Meisenkothen; Novacure
Find other recorded sessions and more information at www.curemeso.org/symposium
